PAD1によって触媒化されたAKT2のシトルリネーションは,卵巣がんにおける卵巣がんのような幹細胞の幹細胞特性維持を促進する
Teng Xue1, Xiaoqiu Liu2, Chao Song3
1Department of Histology and Embryology, College of Basic Medical Science, China Medical University, Shenyang, 110122, China.
Advanced science (Weinheim, Baden-Wurttemberg, Germany)
|August 23, 2025
まとめ
卵巣がんのような幹細胞 (OCSLC) は腫瘍の進行を促します. 研究者らは,ペプチダルギニンデミナーゼ1 (PAD1) がAKT2を活性化させ,卵巣がん (OC) のステム性およびシスプラチン耐性を促進することを発見した. PAD1をターゲットにすることで,化学療法に対する感受性を回復させることができます.
科学分野:
- 腫瘍学
- 分子生物学
- 生物化学
背景:
- 卵巣がんのような幹細胞 (OCSLC) は卵巣がん (OC) の進行,転移,再発の主要な要因です.
- OCSLCの幹性を維持するメカニズムは完全に理解されていません.
- 新しい治療目標の特定は,OCの治療結果の改善に不可欠です.
研究 の 目的:
- OCSLCの幹とOCの悪性腫瘍の調節におけるペプチダルギニンデミナーゼ1 (PAD1) の役割を調査する.
- PAD1がOCSLCに影響を与える分子メカニズムを解明する.
- OCのPAD1信号経路を標的とした治療の可能性を評価する.
主な方法:
- CD133+およびシスプラチン耐性サブセットを含むOC細胞におけるPAD1発現の定量分析.
- シトルリン化とリン酸化を含む,PAD1とAKT2の相互作用の調査.
- CCAAT/Enhancer Binding Protein Beta (CEBPβ) の発現と幹性のマーカーに対するAKT2のダウンストリーム効果の評価
- PAD1の調節が腫瘍を誘発する能力に与える影響を評価するインビトロおよびインビボ試験.
- シスプラチン耐性OC細胞の再敏感化におけるPAD1阻害剤の有効性を試験する.
主要な成果:
- PAD1の発現はOC細胞,特にCD133+およびシスプラチン耐性集団で増加し,幹細胞性マーカーと相関しています.
- PAD1はAKT2に直接結合し,R202でのシトルリネーションを触媒化し,AKT2のリン酸化とキナーゼ活性を増強する.
- 活性化されたAKT2はCEBPβを上調し,幹性に関連する遺伝子の発現を増加させます.
- PAD1阻害,AKT2シトルリネーション阻害,またはAKT2変異により,OC細胞の腫瘍発症能力が著しく低下する.
- PAD1阻害剤はシスプラチンに抵抗するOC細胞をシスプラチン治療に再敏感化する.
結論:
- PAD1は,PAD1/AKT2/CEBPβシグナル伝達軸を通して,OCSCLCの幹性の維持とOC悪性腫瘍の促進に重要な役割を果たします.
- PAD1をターゲットにすることで,シスプラチン抵抗を逆転させ,卵巣がんの腫瘍進行を抑制することができます.
- PAD1/AKT2/CEBPβ経路は,OC再発と化学抵抗を克服するための有望な治療目標です.
関連する概念動画
PI3K/mTOR/AKT Signaling Pathway
3.9K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.9K
mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
Cancer Stem Cells and Tumor Maintenance
5.0K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.0K
M-Cdk Drives Transition Into Mitosis
5.7K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.7K
DNA Damage can Stall the Cell Cycle
9.3K
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.3K
Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K


